Representative Investments
Green Park & Golf enjoys superior deal flow as a result of our past experiences and vast network that has been built on a successful operating and investment history. Our typical investment ranges from $500,000 to $2,000,000 and is used for either start-up or growth capital. Our activity in the investment depends on the needs of the entrepreneur and life stage of the company.
Medical Devices
MicroTransponder Inc
The Vivistim® System, for treatment of post-stroke upper limb impairment, is the first FDA-approved system on the platform. MicroTransponder is committed to expanding access to Vivistim for all stroke survivors, as well as pushing the limits of Paired VNS for other chronic neurologic conditions.
Corvion
Our commitment is to develop a system that is vastly superior to existing devices. We have listened to doctors and patients, and are focused on meeting their needs. For decades doctors, patients, and caregivers have pleaded for a fully implantable LVAD, but no one was able to develop a workable solution. Corvion believed that it was time for a fresh approach.
Novascan
NovaScan’s leadership believes that improving the detection of cancer – be it in initial detection of cancer, during a procedure, or in post-procedural pathology – can improve patient outcomes, increase physician economics, and reduce the cost of care. We are committed to commercializing our platform technology for cancer detection, which we believe offers significant advantages over alternatives in soft tissue cancer detection. NovaScan’s first product, ColeRel, offers Mohs surgeons the opportunity for dramatically faster surgical procedures.
Access Vascular
Access Vascular is developing a suite of venous access devices that use our novel, patented biomaterial which is designed to prevent the most common and costly complications in venous access. Our first product, FDA-cleared HydroPICC, has demonstrated an average of 97% less thrombus accumulation on its surface (based on platelet count)* compared to a standard polyurethane catheter.
Therapeutics
Lantern Pharma
Lantern Pharma Inc. (NASDAQ: LTRN) is a clinical-stage biopharmaceutical company using its proprietary RADR® AI and machine learning platform to transform the cost, pace, and timeline of oncology drug discovery and development. RADR® is used by Lantern and its collaborators to develop and position new drugs and to rescue and reposition drug candidates that others have tried, but failed, to develop. Lantern’s current portfolio consists of four drug candidates and an ADC program across twelve disclosed tumor targets, including the Phase 2 Harmonic™ trial and several additional upcoming Phase 1 clinical trials.
Betaliq, Inc
Betaliq is developing a global portfolio of topical glaucoma treatments based on the unique EyeSol® topical delivery system developed by Novaliq, GMBH. Our unique water-free eye drop technology offers increased residency time and enhanced absorption to provide the needed efficacy, while using less total drug.
Stingray Therapeutics
Stingray is developing innate immunity modulators in the STING (STimulator of Interferon Genes) pathway including potent and selective small molecule inhibitors of ENPP1 (Ectonucleotide Pyrophosphatase / Phosphodiesterase1). ENPP1 is the direct negative regulator of the STING pathway which is essential for activation of the innate immune response.
OncoNano Medicine
OncoNano Medicine is developing a new class of products that exploit pH as a biomarker to diagnose and treat cancer with high specificity. Our product candidates are designed to help patients across the continuum of cancer care and include solid tumor therapeutics, agents for real-time image-guided surgery and T-cell activating immunotherapies.
Barricade Therapeutics
Barricade was founded based on discovery and advancement of novel first-in-class small molecules, by integrating complex molecule synthesis, chemistry, and molecular pharmacology with targeted therapeutic approaches in both cancer and neurology. The company is focused on the development of uniquely innovative targeted drugs for the treatment of patients with cancer and neurodegenerative diseases such as multiple sclerosis (MS).
Iterion Therapeutics
Iterion Therapeutics is a venture-backed, clinical stage biotechnology company developing novel targeted cancer therapeutics. The Company’s lead product, Tegavivint, is a potent and selective inhibitor of nuclear β-catenin,a historically “undruggable” oncology target implicated in cell proliferation, differentiation, immune evasion and stem cell renewal. Many large pharmaceutical companies have tried and failed to develop drugs that are able to effectively bind the protein. The differentiating aspect of Tegavivint is that it does not bind β-catenin directly. Rather, it associates with TBL1 (Transducin Beta-like Protein One), a protein that β-catenin must engage to promote cancer gene expression.
Retension Pharmaceuticals
Retension Pharmaceuticals, Inc. is a private, Phase II clinical stage biopharmaceutical company focused on developing medicines targeting cardiovascular diseases. Their lead product candidate, RTN-001, is a proprietary, orally administered, potent, and selective phosphodiesterase type 5 (“PDE-5”) inhibitor being developed to treat vascular disorders, where improvement in vascular function (reduced peripheral and central blood pressure, improved endothelial function, vasodilatation, and reduced vasoconstriction, and tissue remodeling) will benefit patients.
Diagnostic
Gregor Diagnostics
Gregor has developed a proprietary system to maintain biomarker stability in the seminal fluid. This will allow samples to be collected in the comfort of the patient's home and shipped back to Gregor's laboratory. The sample stability system will allow the prostate cancer screening test to be used by men in even the most remote areas.
Consumer Health
Grow Happy
GrowHappy will serve millions of immunotherapy patients on their lifetime journey to food freedom as the first oral immuno-nutrition snack.
Health IT
Proscia
Proscia is changing the way pathology is practiced. Cancer research and diagnosis is being redefined by a new kind of lab: those that are realizing the promise of artificial intelligence to elevate the pathologist’s role in an era of increasingly personalized medicine and streamline operations to drive unprecedented results.
Tech/SAas
HyperGiant Industries
Hypergiant is an enterprise AI company focused on developing world-changing technology to solve the world's biggest problems in the areas of space, defense, and critical infrastructure. We offer a suite of AI services, software, and solutions that support companies and governments in preparing for the future through AI.
Avanta Risk Management
We developed a new set of tools and processes that use future-focused technology to provide proactive, transparent, customized solutions specifically designed to solve our customer’s unique problems.
Earthview
The Earthview BluBird continuous methane monitoring system is the most reliavble, scalable and affordable CEMS system on the market today.
earthview.io
Exits
SuperGoop
In 2007, founder Holly Thaggard created the first line of advanced UV protective sunscreens with a singular purpose: to prevent sun damage 365 days a year and to say goodbye to the bad stuff, like parabens, petrochemicals, and fragrances. Supergoop! has since grown into a family of highly-technical skincare solutions, using the most powerful antioxidants and scientific ingredients that protect, combat the signs of aging, and promote healthier, youthful skin.
Carpe
The Carpe system of sweat management products helps tackle sweating at the source, no matter when, how, or where. Carpe’s antiperspirants and sweat-absorbing products are frequently recommended by dermatologists, and have been used by thousands with results that have even brought some to tears.
Dignitana
Dignitana develops a patented scalp cooling system, DigniCap® that reduces chemotherapy-induced hair loss. Dignitana's patented DigniCap® system has demonstrated excellent scientific results in clinical studies. More than eight out of ten treated patients were able to retain enough of their hair to eliminate the need for a wig.
Savara
Savara is an emerging specialty pharmaceutical company developing innovative pulmonary drugs for the treatment of serious and life-threatening conditions that are inadequately treated with currently available medicines. The company’s lead product, AeroVanc™ (vancomycin hydrochloride inhalation powder), addresses an unmet clinical need in the treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections in patients with cystic fibrosis (CF). AeroVanc is an inhaled dry powder form of the antibiotic vancomycin in a capsule-based inhaler designed for convenient self-administration. AeroVanc has demonstrated positive safety and tolerability results in a Phase I clinical study conducted in healthy subjects and patients with cystic fibrosis, and Savara is in preparation to initiate a Phase II clinical study.
SendTechnology Inc
Sendinc ensures your messages are encrypted to the highest standards. There's no software required for you or your recipients, and you can use your existing email address. Most importantly - because Sendinc does not store encryption keys - only your recipients have the ability to decrypt your messages.
PerioSciences
PerioSciences researches, formulates, and markets topiCally applied, antioxidant-based oral care and oral hygiene products. Founded in 2008 and headquartered in Dallas, Texas, PerioSciences has established a new category of products – antioxidant-based oral care. PerioSciences is committed to world-class research and to providing the most advanced products for oral health. Using a state-of-the-art business model, PerioSciences partners in sales and distribution with dental professionals, hygienists, and specialists as well as and other medical professionals and medi-spas.
eNictotine Technology Inc
eNT is a healthcare company committed to reducing the harms associated with combustible tobacco products. eNT is developing the next generation of state-of-the-art electronic nicotine delivery products that quickly and dramatically reduce smoking urge while using 40-70% less nicotine than cigarettes or existing e-cigarettes. eNT’s products deliver consistent doses of nicotine and emit no secondhand vapor, giving consumers a discreet and satisfying nicotine experience anytime, anywhere.